NewAmsterdam Pharma Company N.V. (NAMS) Stock

NewAmsterdam Pharma Company N.V. (NAMS) is a Healthcare stock trading at $29.85 (as of 2026-06-18), with a market capitalization of $3.94B and a trailing P/E of -18.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Valuation — source: SEC EDGAR (first-party)
Price$29.85
Market Cap$3.94B
P/E Ratio-18.9
EV / EBITDA-16.2
Price / Book5.92
Price / Sales174.49
DCF Value (model)$-17.66
DCF Upside vs Price-159.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$22.50M
Net Margin-905.7%
Return on Equity-32.0%
Current Ratio9.76
Revenue Growth (YoY)2.1%
EPS Growth (YoY)17.6%
FCF Growth (YoY)-16.0%
Financial Health — source: SEC EDGAR
Altman Z-Score22.58 (safe)
Valuation vs Sector & Industry
Stock P/E-18.9
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-190.3%
vs Industry-209.6%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFrazier Life Sciences Management, L.P. ($542.37M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMayur Amrat Somaiya
Employees68
CountryNL
IPO Date2021-02-09

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • ACADIA Pharmaceuticals Inc. (ACAD)
  • Crinetics Pharmaceuticals, Inc. (CRNX)
  • ADMA Biologics, Inc. (ADMA)
  • Mirum Pharmaceuticals, Inc. (MIRM)
  • Amneal Pharmaceuticals, Inc. (AMRX)
  • Ligand Pharmaceuticals Incorporated (LGND)
  • Corcept Therapeutics Incorporated (CORT)
  • Arcutis Biotherapeutics, Inc. (ARQT)
NAMS earnings history · NAMS institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.